WTIM
VRTX icon

Wilmington Trust Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wilmington Trust Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$614K Hold
6,489
– – 0.12% 126
2014
Q1 		$459K Buy
6,489
+1,600
+33% +$127K 0.09% 168
2013
Q4 		$363K Hold
4,889
– – 0.07% 237
2013
Q3 		$371K Hold
4,889
– – 0.08% 221
2013
Q2 		$391K Buy
+4,889
New +$360K 0.08% 214

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wilmington Trust Investment Management's VRTX Position: Q2 2014 in Review

Wilmington Trust Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2014 at 6,489 shares worth $614K. The position accounts for 0.12% of the portfolio, ranked #126.

Wilmington Trust Investment Management first reported a position in VRTX in Q2 2013 and has held it in 5 quarters since. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

  • Wilmington Trust Investment Management held 6,489 shares of Vertex Pharmaceuticals worth $614K as of Q2 2014.
  • Wilmington Trust Investment Management left its Vertex Pharmaceuticals share count unchanged in Q2 2014.
  • Vertex Pharmaceuticals made up 0.12% of Wilmington Trust Investment Management's portfolio in Q2 2014, its #126 holding.
  • Wilmington Trust Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • 411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on Wilmington Trust Investment Management's 13F filing for Q2 2014, filed 13 Aug 2014.